TL;DR: Parallel Bio is a Y Combinator Summer 2021 startup Using the immune system to cure disease, currently active with a team of 20.
Using the immune system to cure disease
Last verified:
Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s platform overcomes the core limitations of traditional animal testing, which fails to encapsulate the complexity of human biology. The company is building internal pipelines of novel disease targets and drug candidates in both cancer and autoimmune disease, while collaborating with pharmaceutical companies to evaluate therapies directly in human systems to reduce the cost and risk of clinical trials. Based in San Francisco, the company was founded in 2021 by two of the world…
Built by LemStudio
Yes. Parallel Bio was funded by Y Combinator in the Summer 2021 batch. Using the immune system to cure disease
Parallel Bio is pioneering human-first drug discovery by creating the first map of human biology. Using groundbreaking biological and computational tools that track real clinical outcomes, the company generates data that enable earlier, more reliable decisions about disease biology and drug development. Parallel Bio’s…
Parallel Bio was part of Y Combinator's Summer 2021 batch.
Parallel Bio has a team of 20 people according to Y Combinator's directory.
Parallel Bio is currently listed as Active with a team of 20 in Y Combinator's directory.
Loading interactive view…